Abstract:Xiao-Yang Xu, &ast Ze Wang, &ast Chen-You Liu, &ast Hao-Dong Wu, Ze-Xin Hu, Yu-Ying Lin, Shuai Zhang, Jian Shen, Bin-Yan Zhong, Xiao-Li Zhu Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiao-Li Zhu, Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Street, Suzhou, 215006, People's Republic of China, Email Objective: To explore changing trends in circulating immune indicators of hepatocellular carcinoma (HCC) undergoing TACE plus immune checkpoint inhibitors (ICIs) and anti-VEGF antibodies/TKIs and to elucidate the relationship between immune response and tumor prognosis. Materials: This single-center retrospective study included patients with unresectable HCC undergoing TACE plus ICIs and anti-VEGF antibodies/TKIs from March 11, 2019, to February 15, 2024. Peripheral blood samples were collected at baseline and every cycle, from which blood cell counts and immune indicators were analyzed. The primary outcome was the objective response rate (ORR) at the first evaluation. According to the first evaluation based on mRECIST, patients were classified into PD, SD, and OR groups for analysis. Further subgroup analysis was performed on the OR group based on whether experiencing progression after the first evaluation. Lymphocyte subsets were measured by flow cytometry. Immunoglobulins were measured using the immune turbidimetric method. The neutrophil-to-lymphocyte ratio (NLR) was measured by the complete blood count. Simple linear regression was employed to examine the dynamic trends. Results: A total of 63 patients were enrolled, with an ORR of 55.6% and a disease control rate (DCR) of 87.3% at the first evaluation. The median overall survival (mOS) was 27.5 months (95% CI: 22.5– 32.5 months). In the OR group (n=35), more active immune responses, expressed in a decrease in CD3 − CD19 + ( p =0.004), CFB ( p =0.027), NLR ( p < 0.001) and an increase in Ig λ ( p =0.010), Ig κ ( p =0.037), Ig A ( p =0.005), Ig G ( p =0.006), were related to better prognosis, while similar patterns seen in the OR-nPD subgroup. Concurrently, no significant differences were noted in the PD group (n=8). Conclusion: The combination therapy may modify the tumor microenvironment of HCC. Changing trends in circulating immune indicators and NLR can serve as potential biomarkers for predicting tumor response and guiding clinical treatment. Keywords: immune indicator, TACE, immune checkpoint inhibitors, tyrosine kinase inhibitors, tumor microenvironment Hepatocellular carcinoma (HCC) is characterized by high incidence and mortality rates, with approximately half of the global new cases and deaths occurring in China each year. 1 HCC often presents insidiously, and over 80% of patients are diagnosed at an advanced stage, resulting in a low curative resection rate and poor prognosis. 2 According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the recommended standard treatment for patients with intermediate HCC and is also widely used for advanced HCC. 3,4 TACE works by embolizing the tumor blood supply, leading to tumor ischemia and hypoxia, thereby inhibiting tumor progression while chemotherapy drugs can be administered locally and accurately. 5 However, the resultant hypoxic environment can stimulate angiogenic pathways, such as vascular endothelial growth factor (VEGF), reducing the number and function of immune cells. Combining immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) can improve the hypoxic and immunosuppressive tumor microenvironment (TME) and inhibit tumor angiogenesis. 6 Anti-VEGF plays its role as an anti-vascular, anti-angiogenic, or anti-permeability factor in preventing tumor growth and metastasis. 7 Therefore, the combination therapy of TACE plus ICIs and anti-VEGF antibodies/TKIs holds the potential for further improving the efficacy of treatment for unresectable HCC (uHCC). 8,9 Some studies, such as EMERALD-1, CHANCE001, and CHANCE2201, have further demonstrated that this combination therapy significantly improves the prognosis of patients with uHCC. 10–12 The liver, being an immune-privileged organ, often exhibits a lack or even absence of tumor-infiltrating lymphocytes in both the HCC tumor nests and surrounding stroma, making it difficult to generate functional tumor-specific T cells and thus an effective anti-tumor immune response. 13–15< -Abstract Truncated-

A Hypoxia-Related miRNA-mRNA Signature for Predicting the Response and Prognosis of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma

MiR-125b Loss Activated HIF1/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma

The Role of GNMT and MMP12 Expression in Determining TACE Efficacy: Validation at Transcription and Protein Levels

Construction and validation of transcription‐factor‐based prognostic signature for TACE non‐response and characterization of tumor microenvironment infiltration in hepatocellular carcinoma

Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients

Screening hypoxia-related genes as prognostic biomarkers and modeling the individualized prognostic predictor in hepatocellular carcinoma

MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma

Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Differential Expression of Hepatic Cancer Stemness and Hypoxia Markers in Residual Cancer after Locoregional Therapies for Hepatocellular Carcinoma

Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma

Prognosis of Patients with Hepatocellular Carcinoma Treated with TACE: A New Score Combining Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin

Immune Indicator Changes in Hepatocellular Carcinoma Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs: A Prognostic Biomarker Analysis

Prognostic Hypoxia-Angiogenesis-Related Gene Signature in Hepatocellular Carcinoma, in Which HILPDA Contributes to Tumor Progression

Identification of Hypoxia-Related Prognostic Signature and Competing Endogenous RNA Regulatory Axes in Hepatocellular Carcinoma

Dissecting a hypoxia-related angiogenic gene signature for predicting prognosis and immune status in hepatocellular carcinoma

Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma

Construction of a Combined Hypoxia-related Genes Model for Hepatocellular Carcinoma Prognosis.

Gene Signature Predictive of Hepatocellular Carcinoma Patient Response to Transarterial Chemoembolization

HIF-1α and VEGF Levels for Monitoring Hepatocellular Carcinoma Treatment Response to Transcatheter Arterial Chemoembolization

Development of predictive biomarkers for transarterial chemoembolization efficacy in hepatocellular carcinoma